The FDA has also granted orphan drug designation to LYT-200 for the treatment of AML a BOSTON, January 08, 2025--PureTech to present at 43rd annual J.P. Morgan Healthcare Conference. BOSTON ...
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200 is ...
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback